Supplementary Figures – Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis
|
Supplementary Figure S1. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis Pairwise meta-analysis for first line therapy. Forestplot of PFS (a1), OS (a2) and ORR (a3) for overall population. Forestplot of PFS (b1), OS (b2) for PD-L1 negative population. Forestplot of PFS (c1), OS (c2) for PD-L1 intermediate population. Forestplot of PFS (d1), OS (d2) for PD-L1 high population. Forestplot of PFS (e1), OS (e2) for liver metastasis population. Forestplot of grade 3 to 5 tr-AEs (f). *PFS, progression free survival; OS, overall survival; ORR, objective response rate; PD-L1, program death ligand 1; tr-AEs, treatment-related adverse events.
Supplementary Figure S2–S11. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis |
